Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Amgen anticipates Lumakras (Amgen lung cancer drug) to become a cornerstone medicine as the company aims to develop multiple medications for the targets.
This first-of-its-kind collaboration will leverage the talent and innovation at companies such as Tessera Therapeutics to advance multiple candidates to human proof of concept.
Clade Therapeutics will use its funds to further its research and development on cancer treatments, while GRO Biosciences will focus on chronic diseases.
Immunology expert Constance Cullen of Schering-Plough Corp. revealed that Theranos inappropriately attached Schering-Plough’s logo to data issued to potential investors.
In November 2019, Emory realized this experimental drug could have significant potential in respiratory viruses such as COVID-19.
Shoreline Biosciences secured $140 million in financing to accelerate the growth of its induced pluripotent stem cells (iPSC)-based immunotherapies and support the expansion of its manufacturing capabilities.
The partnership will leverage Metagenomi’s novel gene editing technology and Moderna’s mRNA platform, in addition to its lipid nanoparticle delivery technologies.
Novartis has forged a collaboration with U.K.-startup Dunad Therapeutics to develop next-generation targeted protein-degradation therapies in a deal valued at up to $1.3 billion.
This novel diagnostic technology uses augmented reality and a smartphone or tablet to administer cognitive and functional tests.
Inovio shares are down about 2% in premarket trading after cancellation reports of a DNA cancer vaccine collab with AstraZeneca.